Navigation Links
Irving Dark Named Vice President of Cytel Clinical Research Services
Date:1/16/2008

Proven Executive Brings Both Clinical Trial Experience and Business

Development Leadership to Clinical Trial Services Management Role

CAMBRIDGE, Mass., Jan. 16 /PRNewswire/ -- Cytel, Inc. announced today that clinical research and business development executive Irving Dark has accepted the role of Vice President of Cytel Clinical Research Services. Mr. Dark brings to Cytel 15-years of management experience guiding drug, biologic and medical device products successfully through the development process as well as growing commercial clinical research organizations.

In his new position, Mr. Dark will head and drive the growth of Cytel's cutting-edge clinical trial design and implementation services to the biopharmaceutical industry.

Prior to joining Cytel, Mr. Dark was Vice President, Business Development and Operations for Veristat, Inc. During his tenure he established and oversaw the company's Data Management, Project Management, and Business Development departments. Mr. Dark was integrally involved with Veristat's Corporate Compliance activities to ensure adherence with regulatory and GCP guidelines, and was instrumental in the company's oncology and influenza contracts, and the Acambis smallpox vaccine program.

Previously, Mr. Dark held several key positions at full-service trial leader PAREXEL, rising from statistical programming management to overseeing the planning and conduct of phase 1, 2, and 3 global clinical trials.

"Irving's experience in trial management and his knowledge of the clinical development needs of the biopharmaceutical industry are ideally suited to growing Cytel's innovative clinical research services" said Ranganath Nayak, Chief Executive Officer of Cytel.

"Cytel has an impressive track record delivering innovative solutions to the biopharmaceutical industry," said Irving Dark. "Cytel's experience designing innovative clinical trials and its advanced analytical capabilities differentiate our trial services from those offered by traditional CRO's. I am delighted to be joining the management team at such an exciting time for the company."

About Cytel

Celebrating its 20th anniversary, Cytel Inc. is a leading provider of clinical trial consulting services, specialized statistical software, and outsourced clinical study reports for the biopharmaceutical, medical device, academic, and research institute markets. Cytel's validated trial designs and implementation services reduce development time and costs while increasing the probability of clinical success. Cytel Inc. is headquartered in Cambridge, MA, with facilities in Philadelphia, PA and Pune, India.


'/>"/>
SOURCE Cytel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Panacea Pharmaceuticals Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazines Ten Biggest Medical Breakthroughs of 2007
2. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
3. Kent Riddle Named To Piedmont Triad Biotechnology Development Group
4. Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train
5. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
6. K-States Subbaratnam Muthukrishnan and Barbara Valent Named Fellows of the American Association for the Advancement of Science
7. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
8. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
9. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
10. DuPont Named Among Top Biotechnology Employers by Science Magazine
11. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):